IPP Bureau
Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development
By IPP Bureau - November 16, 2024
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications
By IPP Bureau - November 16, 2024
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America
By IPP Bureau - November 16, 2024
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
By IPP Bureau - November 16, 2024
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
By IPP Bureau - November 16, 2024
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM
By IPP Bureau - November 16, 2024
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu
By IPP Bureau - November 15, 2024
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr
By IPP Bureau - November 15, 2024
NABH integrates FOGSI’S maternal health standards across its certification programs
By IPP Bureau - November 15, 2024
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
By IPP Bureau - November 14, 2024
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024
By IPP Bureau - November 14, 2024
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
By IPP Bureau - November 14, 2024
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
By IPP Bureau - November 14, 2024
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Cupid Q2 FY25 income up 29.7%; PAT up 96.2%
By IPP Bureau - November 13, 2024
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
By IPP Bureau - November 13, 2024
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
